Management of Wilms tumor: current standard of care.
Wilms tumor is the most common renal malignancy in children. In the 1930s, overall survival for children with Wilms tumor was approximately 30%. Use of multidisciplinary therapy, guided by results from multi-institutional, randomized trials, has substantially improved overall survival to about 90%. Management of Wilms tumor differs substantially between Europe and the US. In Europe, the International Society of Pediatric Oncology protocols call for management of patients with presumptive Wilms tumor with neoadjuvant chemotherapy followed by nephrectomy and further chemotherapy. In the US, protocols developed by the National Wilms Tumor Study Group advise primary nephrectomy followed by a chemotherapy regimen tailored to the pathologic tumor stage. Despite these disparate strategies, overall survival is similar in patients managed according to European and US protocols. Patients with Wilms tumor now have excellent survival. Therefore, current goals aim to reduce the morbidity associated with therapy. Important complications of treatment for Wilms tumor include cardiomyopathy, renal failure, and increased risk of a secondary malignancy. Currently, the role of laparoscopic surgery in management of Wilms tumor remains extremely limited.
Stanford University Medical Center, Stanford, CA 94305-5118, USA.
Geoffrey
G
Sonn
Linda M D
LM
Shortliffe
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D019468:Disease Management; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D009392:Nephrectomy / Q000639:trends; D009396:Wilms Tumor / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*
D000970:Antineoplastic Agents